Max Feinstein, DO
Neuromusculoskeletal Medicine & OMM · Bloomfield Hills, MINPI 1861839912
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 480 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 46 manufacturers, the largest accounting for just 10.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,430 and has fallen 66.1% since, to $485 in 2025. Among neuromusculoskeletal medicine & omm clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 480 payments — averaging $16.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$868
- AbbVie$826
- Novo Nordisk$701
- GSK$613
- Pfizer$445
- Nestle Healthcare Nutrition Inc.$422
- plus $4K from 40 others
What the payments were for
- Food & beverage$8,045100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,045 in reported general payments places this provider in the 95th percentile of 41 neuromusculoskeletal medicine & omm providers in Michigan.
See all neuromusculoskeletal medicine & omm providers in Michigan →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 54 | $59,425 |
| EliquisApixaban | 42 | $36,074 |
| JardianceEmpagliflozin | 25 | $29,700 |
| TradjentaLinagliptin | 36 | $27,780 |
| EntrestoSacubitril/Valsartan | 28 | $27,085 |
| MounjaroTirzepatide | 15 | $26,879 |
| LinzessLinaclotide | 34 | $25,083 |
| OzempicSemaglutide | 19 | $23,117 |
| BelsomraSuvorexant | 29 | $17,379 |
| GlyxambiEmpagliflozin/Linagliptin | 18 | $15,774 |
| TrulicityDulaglutide | 15 | $14,294 |
| Repatha SureclickEvolocumab | 18 | $14,241 |
| GemtesaVibegron | 18 | $14,164 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $10,962 |
| XareltoRivaroxaban | 16 | $9,144 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Glyxambi | $183 | $73,25479 claims |
| AstraZenecaFarxiga | $868 | $59,42554 claims |
| Lilly USA, LLCMounjaro, Trulicity | $398 | $41,17330 claims |
| PfizerEliquis | $445 | $36,07442 claims |
| NovartisEntresto | $214 | $27,08528 claims |
| AbbVieLinzess | $826 | $25,08334 claims |
| MerckBelsomra, Janumet Xr | $396 | $23,69540 claims |
| Novo NordiskOzempic | $701 | $23,11719 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $613 | $19,36432 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $222 | $14,16418 claims |
| Johnson & JohnsonXarelto | $117 | $9,14416 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 41 neuromusculoskeletal medicine & omm providers in Michigan.
Other neuromusculoskeletal medicine & omm in Bloomfield Hills
- Mark BradenGrand Rapids$8K
- Sidney BroderGrand Blanc$2K
- Reddog SinaEast Lansing$1K
- Mark BeardNovi$533
- David NebbelingLansing$479
- David HicklingClinton Twp$477
- Zachary WilsonEast Lansing$448
- Benjamin VisgerMuskegon$444
- Amy DeanMuskegon$340
- Justin RuttEast Lansing$308
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.